Rosiglitazone and cardiovascular risk

New England Journal of Medicine

Volumn 356, Issue 24, 2007, Pages 2522-2524

  Psaty, Bruce M ^a,b   Furberg, Curt D ^c  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b CENTER FOR HEALTH STUDIES   (United States)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN; MURAGLITAZAR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PLACEBO; ROSIGLITAZONE; TORCETRAPIB;

ADVERSE OUTCOME; ANEMIA; ATTRIBUTABLE RISK; BODY WEIGHT; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONFIDENCE INTERVAL; DOSE RESPONSE; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; FLUID RETENTION; GLUCOSE METABOLISM; HEART INFARCTION; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; INSULIN RESISTANCE; LIPID BLOOD LEVEL; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; SIDE EFFECT; SYSTEMATIC REVIEW; TREATMENT FAILURE;

EID: 34250178250     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMe078099     Document Type: Article

References (19)

1. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457-71.
2. Yki-Järvinen H. Thiazolidinediones. N Engl J Med 2004;351:1106-18.
3. Diamant M, Heine RJ. Thiazolidinediones in type 2 diabetes mellitus: current clinical evidence. Drugs 2003;63:1373-405.
4. The DREAM (Diabetes Reduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006;368:1096-105. [Erratum, Lancet 2006;368:1770.]
5. Nathan DM. Thiazolidinediones for initial treatment of type 2 diabetes? N Engl J Med 2006;355:2477-80.
6. Psaty BM, Furberg CD, Kuller LH, et al. Traditional risk factors and subclinical disease measures as predictors of first myocardial infarction in older adults: the Cardiovascular Health Study. Arch Intern Med 1999;159:1339-47.
7. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005;353:2643-53.
8. Psaty BM, Weiss NS, Furberg CD, et al. Surrogate end points, health outcomes, and the drug approval process for the treatment of risk factors for cardiovascular disease. JAMA 1999;282:786-90.
9. Nissen SE, Wolski K, Topol EJ. Effect of muraglitazar on death and major adverse cardiovasculr events in patients with type 2 diabetes mellitus. JAMA 2005;294:2581-6.
10. Nissen SE, Tardif J-C, Nicholls SJ, et al. Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med 2007;356:1304-16.
11. McAdam BF, Catella-Lawson F, Mardini IA, Kapoor S, Lawson JA, FitzGerald GA. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci U S A 1999;96:272-7. [Erratum, Proc Natl Acad Sci U S A 1999;96:5890.]
12. Psaty BM, Furberg CD. COX-2 inhibitors - lessons in drug safety. N Engl J Med 2005;352:1133-5.
13. Steenburg C. The Food and Drug Administration's use of postmarketing (Phase IV) study requirements: exception to the rule? Food Drug Law J 2006;61:295-384.
14. Psaty BM, Weiss NS, Furberg CD. Recent trials in hypertension: compelling science or commercial speech? JAMA 2006;295:1704-6.
15. FDA requested postmarketing studies in 73% of recent new drug approvals. Impact report. Vol. 6. No. 4. Boston: Tufts Center for the Study of Drug Development, July/August 2004:1-4.
16. Food and Drug Administration. Report on the performance of drug and biologics firms in conducting postmarketing commitment studies: availability. Fed Regist 2007;72(22):5069-70.
17. Food and Drug Administration Revitalization Act, S1082. U.S. Senate bill. (Accessed May 24, 2007, at http://frwebgate.access.gpo.gov/cgi-bin/getdoc.cgi? dbname=110_cong_bills&docid=f:s1082es.txt.pdf.)
18. Baciu A, Stratton K, Burke SP, eds. The future of drug safety: promoting and protecting the health of the public. Washington, DC: National Academies Press, 2007.
19. Wood AJJ. A proposal for radical changes in the drug-approval process. N Engl J Med 2006;355:618-23. [Erratum, N Engl J Med 2006;355:2712.]